Equities analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to post earnings of ($0.97) per share for the current quarter, according to Zacks. Three analysts have made estimates for Ascendis Pharma A/S’s earnings. The lowest EPS estimate is ($1.38) and the highest is ($0.28). Ascendis Pharma A/S reported earnings of ($1.31) per share during the same quarter last year, which would indicate a positive year over year growth rate of 26%. The firm is expected to report its next earnings report on Wednesday, May 29th.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full-year earnings of ($3.93) per share for the current financial year, with EPS estimates ranging from ($5.58) to ($0.42). For the next year, analysts expect that the firm will post earnings of ($3.58) per share, with EPS estimates ranging from ($6.81) to ($0.08). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.30. Ascendis Pharma A/S had a negative net margin of 1,275.08% and a negative return on equity of 40.86%. The company had revenue of $12.00 million during the quarter.
ASND opened at $124.38 on Friday. Ascendis Pharma A/S has a fifty-two week low of $53.21 and a fifty-two week high of $131.76. The firm has a market capitalization of $5.09 billion, a price-to-earnings ratio of -32.89 and a beta of 0.94.
Hedge funds have recently added to or reduced their stakes in the company. venBio Select Advisor LLC increased its stake in shares of Ascendis Pharma A/S by 0.8% during the fourth quarter. venBio Select Advisor LLC now owns 1,980,000 shares of the biotechnology company’s stock worth $124,047,000 after purchasing an additional 16,664 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth about $204,000. Virtus ETF Advisers LLC purchased a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth about $300,000. Morgan Stanley increased its stake in shares of Ascendis Pharma A/S by 53.6% during the third quarter. Morgan Stanley now owns 47,100 shares of the biotechnology company’s stock worth $3,338,000 after purchasing an additional 16,434 shares in the last quarter. Finally, FMR LLC increased its stake in shares of Ascendis Pharma A/S by 1.2% during the fourth quarter. FMR LLC now owns 4,203,246 shares of the biotechnology company’s stock worth $263,333,000 after purchasing an additional 50,984 shares in the last quarter. 94.86% of the stock is owned by institutional investors and hedge funds.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Featured Article: What is the Current Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.